Astellas has said it will book a $170 million ... both in early-stage clinical development – along with DMD gene therapies AT702, AT751 and AT753. The full financial impact of the delay to ...

With the safety of gene therapies thrown into the spotlight by a series of FDA clinical holds, Astellas has said that an interim readout in a phase 1/2 trial of its Pompe disease candidate AT845 ...

DelveInsight's Pompe Disease pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline ...

BOSTON & MONTREAL, June 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, ...

DataM Intelligence | competitive Intelligence Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dys ...

JMP Securities Silvan Tuerkcan revised the firm’s view on Taysha Gene Therapies, Inc. (NASDAQ:TSHA), raising the price target ...

BOSTON & MONTREAL, May 28, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, ...

The Business Research Company’s Juvenile Macular Degeneration Treatment Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, May 27, 2025 ...

Today, a brief rundown of news involving Astellas Pharma and Keros Therapeutics, as well as updates from Stealth Biotherapeutics, PepGen and Taysha Gene Therapies that you may have missed. A growing ...

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Highlights from Astellas at the 2025 ASCO Annual Meeting will include a strong focus on Overall Survival (OS) data updates, confirming the value that these therapies bring to patients: The ARCHES ...